Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 31, 2016 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen® Phase III Trial in Patients with CFS/ME

51% of patients in the high responder subset receiving Ampligen vs. 18% of placebo patients demonstrated improvement of at least 25% in exercise tolerance Data presented at the 12th...